ゴーシェ病の疫学的予測

◆英語タイトル:EpiCast Report: Gaucher Disease - Epidemiology Forecast to 2024
◆商品コード:GDHCER103-15
◆発行会社(調査会社):GlobalData
◆発行日:2015年11月6日
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥447,440見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥894,880見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD11,985 ⇒換算¥1,342,320見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、ゴーシェ病の疫学的市場予測について調査・分析し、以下の構成でお届けいたします。

・イントロダクション
・ゴーシェ病の概要
・リスク要因及び併存症
・主要地域の動向
・疫学的予測方法
・ゴーシェ病の疫学的予測結果(有病率など)
・考察(結論、分析の限界・強み)
【レポートの概要】

EpiCast Report: Gaucher Disease – Epidemiology Forecast to 2024

Summary

Gaucher Disease (GD) is a rare, inherited lysosomal storage disorder (LSD) that is classified into three forms – Types 1, 2, and 3 – which are distinguished by their symptoms, severity, and neurological involvement. GD affects the ability of cells to break down a specific type of fat, glucocerebroside (GC), as a result of the deficiency or limited activity of the enzyme glucocerebrosidase (GCase). This leads to the harmful accumulation of GC, which is also known as glucosylceramide, in the lysosomes, most commonly in the macrophages and monocytes, throughout the body. The most significant difference between the three types of GD is whether or not there is neurological involvement.

GlobalData epidemiologists forecast that the total prevalent cases of Type 1 GD in the 7MM will increase from 12,036 cases in 2014 to 13,006 cases in 2024, with the majority of cases occurring in the US and Israel. Types 2 and 3 GD are even more rare than Type 1, with only 121 cases of Type 2 and 613 cases of Type 3 across the 7MM in 2014. GlobalData epidemiologists predict that the total prevalent cases of Type 2 GD in the 7MM will increase from 121 cases in 2014 to 125 cases in 2024, and that the total prevalent cases of Type 3 GD in the 7MM will increase from 613 cases in 2014 to 640 cases in 2024. The disease affects men and women in equal numbers across the 7MM.

GlobalData epidemiologists used the available data on GD to the best extent possible to provide the most insightful epidemiological forecast for the total prevalent cases and type-specific cases of the disease in the 7MM. GlobalData epidemiologists conducted an exhaustive literature review, and used the most appropriate prevalence estimates. For Israel, where there is a high concentration of Ashkenazi Jews, GlobalData epidemiologists segmented the population into the general population and the Ashkenazi Jewish population, and used population-specific prevalence estimates for the forecast. This provides a more accurate estimate of the prevalence of GD in Israel, considering the higher disease prevalence among the Ashkenazi Jews as compared with the general population. For this forecast, GlobalData epidemiologists used a total GD prevalence estimate, which provides a truer picture of the disease burden within the 7MM.

Scope

- The Gaucher Disease (GD) EpiCast Report provides an overview of the risk factors and global trends of GD in the 7MM (US, France, Germany, Italy, Spain, UK, and Israel). It includes a 10-year epidemiology forecast for the total prevalent cases of Type 1, 2, and 3 GD, segmented by age and sex in these markets.
- The GD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The GD EpiCast report will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global GD market.
- Quantify patient populations in the global GD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GD therapeutics in each of the markets covered.
- Identify the percentage of GD prevalent cases by disease type.

【レポートの目次】

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 7
2.3 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 11
3.3.1 US 12
3.3.2 5EU 12
3.3.3 Israel 12
3.4 Forecast Methodology 13
3.4.1 Sources Used 13
3.4.2 Sources Not Used 14
3.4.3 Forecast Assumptions and Methods 15
3.5 Epidemiological Forecast for Gaucher Disease (2014-2024) 16
3.5.1 Total Prevalent Cases of Type 1 Gaucher Disease 16
3.5.2 Age-Specific Total Prevalent Cases of Type 1 Gaucher Disease 18
3.5.3 Sex-Specific Total Prevalent Cases of Type 1 Gaucher Disease 20
3.5.4 Age-Standardized Total Prevalence of Type 1 Gaucher Disease 22
3.5.5 Total Prevalent Cases of Type 2 Gaucher Disease 23
3.5.6 Sex-Specific Total Prevalent Cases of Type 2 Gaucher Disease 25
3.5.7 Total Prevalent Cases of Type 3 Gaucher Disease 26
3.5.8 Age-Specific Total Prevalent Cases of Type 3 Gaucher Disease 28
3.5.9 Sex-Specific Total Prevalent Cases of Type 3 Gaucher Disease 30
3.5.10 Age-Standardized Total Prevalence of Type 3 Gaucher Disease 31
3.6 Discussion 32
3.6.1 Epidemiological Forecast Insight 32
3.6.2 Limitations of the Analysis 33
3.6.3 Strengths of the Analysis 34
4 Appendix 35
4.1 Bibliography 35
4.2 About the Authors 37
4.2.1 Epidemiologists 37
4.2.2 Reviewers 37
4.2.3 Global Director of Therapy Analysis and Epidemiology 38
4.2.4 Global Head of Healthcare 39
4.3 About GlobalData 40
4.4 About EpiCast 40
4.5 Disclaimer 41

1.1 List of Tables
Table 1: 7MM, Sources Used to Forecast the Total Prevalent Cases of Gaucher Disease 13
Table 2: 7MM, Total Prevalent Cases of Type 1 Gaucher Disease, All Ages, Both Sexes, N, 2014-2024 17
Table 3: 7MM, Total Prevalent Cases of Type 1 Gaucher Disease, by Age, Both Sexes, N (Row %), 2014 19
Table 4: 7MM, Total Prevalent Cases of Type 1 Gaucher Disease, All Ages, N (Row %), by Sex, 2014 21
Table 5: 7MM, Total Prevalent Cases of Type 2 Gaucher Disease, Age ≤4 Years, Both Sexes, N, 2014-2024 24
Table 6: 7MM, Total Prevalent Cases of Type 3 Gaucher Disease, Age <40 Years, Both Sexes, N, 2014-2024 27
Table 7: 7MM, Total Prevalent Cases of Type 3 Gaucher Disease, by Age, Both Sexes, N (Row %), 2014 29

1.2 List of Figures
Figure 1: 7MM, Total Prevalent Cases of Type 1 Gaucher Disease, All Ages, Both Sexes, N, 2014-2024 18
Figure 2: 7MM, Total Prevalent Cases of Type 1 Gaucher Disease, by Age, Both Sexes, N 20
Figure 3: 7MM, Total Prevalent Cases of Type 1 Gaucher Disease, All Ages, N, by Sex, 2014 22
Figure 4: 7MM, Age-Standardized Total Prevalence of Type 1 Gaucher Disease (%), All Ages, by Sex, 2014 23
Figure 5: 7MM, Total Prevalent Cases of Type 2 Gaucher Disease, Age ≤4 Years, Both Sexes, N, 2014-2024 25
Figure 6: 7MM, Total Prevalent Cases of Type 2 Gaucher Disease, All Ages, by Sex, N, 2014 26
Figure 7: 7MM, Total Prevalent Cases of Type 3 Gaucher Disease, Age <40 Years, Both Sexes, N, 2014-2024 28
Figure 8: 7MM, Total Prevalent Cases of Type 3 Gaucher Disease, by Age, Both Sexes, N, 2014 30
Figure 9: 7MM, Total Prevalent Cases of Type 3 Gaucher Disease, Age <40 Years, by Sex, N, 2014 31
Figure 10: 7MM, Age-Standardized Total Prevalence of Type 3 Gaucher Disease (%), Age <40 Years, by Sex, 2014 32

★調査レポート[ゴーシェ病の疫学的予測]販売に関する免責事項
★調査レポート[ゴーシェ病の疫学的予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆